The Scleroderma Patient-centered Intervention Network (SPIN) Support Group Leader Education Program Feasibility Trial
NCT03508661 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2020-02-12
Summary
Many people living with a rare disease turn to peer-led support groups to cope with their condition and access educational resources. Systemic sclerosis (SSc), or scleroderma, is a rare autoimmune connective tissue disease where peer-led support groups play an important role. There are currently approximately 200 SSc support groups in Canada and the US, most of which are led by people with SSc. Many SSc patients, however, cannot access support groups. In other cases, support groups are not sustained due to factors that include the burden on group leaders living with a serious, unpredictable disease and limited group leadership skills of some untrained leaders. Our partners from Scleroderma Canada and the Scleroderma Foundation in the US are committed to improving support group accessibility and effectiveness. These organizations maintain a list of active support groups, but currently do not provide training or other resources to groups or their leaders. To address this gap, our team, including investigators and patients from the Scleroderma Patient-centered Intervention Network (SPIN), developed the Scleroderma Support group Leader EDucation (SPIN-SSLED) Program, which is designed to improve support group leader confidence and self-efficacy, reduce burnout, improve emotional well-being, and improve health-related quality of life.
In the planned full-scale randomized controlled trial (RCT) that will follow our feasibility trial, we will evaluate whether the SPIN-SSLED Program is effective in improving SSc support group leaders' self-efficacy for carrying out their leader role (primary) and if it reduces burnout, improves emotional well-being, and improves health-related quality of life (secondary). Thus, the SPIN-SSLED Feasibility Trial answers the following research questions: (1) Is a full-scale SPIN-SSLED RCT feasible? (2) Are adaptations needed to the research design for the planned full-scale RCT? (3) Are there ways to improve the SPIN-SSLED Program for delivery in the planned full-scale RCT based on input of support group leaders who participate in the feasibility trial?
Conditions
- Scleroderma
- Systemic Sclerosis
Interventions
- OTHER
-
SPIN-SSLED Program
The program includes 13 modules that will be delivered live via webinar over the course of the 3-month program. Each module will be delivered in a 60- to 90-minute session. Module topics include (1) the leader's role; (2) starting a support group; (3) structuring a support group meeting; (4) scleroderma 101; (5) successful support group culture; (6 \&7) managing support group dynamics I and II; (8) grief and crisis in scleroderma; (9) marketing and recruitment; (10) the continuity of the group; (11) supporting yourself as a leader; (12) virtual support group meetings, (13) support group leader resources. Participants will receive a workbook, be shown filmed vignettes, and will have access to an online resource center.
Sponsors & Collaborators
-
Lady Davis Institute
lead OTHER
Principal Investigators
-
Brett Thombs, PhD · Jewish General Hospital and McGill Universit
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-04-18
- Primary Completion
- 2018-08-10
- Completion
- 2018-08-10
Countries
- Canada
Study Locations
More Related Trials
-
Evaluating Tools to Communicate Scleroderma Research Results to Patients - Trial #1
NCT06373263 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
EFFECTS OF THE MICRO REINJECTION OF AUTOLOGOUS ADIPOSE TISSUE IN THE FACE OF PATIENTS WITH SYSTEMIC SCLEROSIS
NCT02206672 ·Status: UNKNOWN ·Phase: NA
-
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
NCT05559580 ·Status: COMPLETED ·Phase: PHASE2
-
Making it Work Program for Systemic Sclerosis
NCT06338722 ·Status: COMPLETED ·Phase: NA
-
Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
NCT06297096 ·Status: RECRUITING ·Phase: PHASE3
-
Skin Biopsy Specimens as Biomarkers of Systemic Sclerosis and Response to Mycophenolate Mofetil
NCT00853788 ·Status: COMPLETED
-
Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy
NCT03509064 ·Status: RECRUITING
-
Taking Charge of Systemic Sclerosis
NCT02494401 ·Status: COMPLETED ·Phase: NA
-
Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis
NCT00318188 ·Status: COMPLETED ·Phase: NA
-
6-minute Pegboard Ring Test in Patients with Scleroderma
NCT06588959 ·Status: NOT_YET_RECRUITING
-
Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
NCT03221257 ·Status: COMPLETED ·Phase: PHASE2
-
Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis
NCT02558543 ·Status: TERMINATED ·Phase: PHASE2
-
Exercise in People With Systemic Sclerosis
NCT05234671 ·Status: COMPLETED ·Phase: NA
-
A Study of the Safety and Tolerability of MEDI-551 in Scleroderma
NCT00946699 ·Status: COMPLETED ·Phase: PHASE1
-
Early Diagnosis of SSc in the General Rheumatology Clinic - Pilot
NCT06291142 ·Status: COMPLETED
-
Stem Cell Factor, a Potential Biological Marker of Skin Involvement in Systemic Sclerosis?
NCT05482594 ·Status: UNKNOWN
-
Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis
NCT02212249 ·Status: COMPLETED ·Phase: NA
-
Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis
NCT00667134 ·Status: COMPLETED
-
A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma
NCT01881529 ·Status: COMPLETED
-
Effects of Topical SLPI on Skin Wounds
NCT00005569 ·Status: COMPLETED ·Phase: PHASE1
-
Primary Sjögren Syndrome
NCT01989819 ·Status: COMPLETED
-
Injection of Autologous Adipose-derived Stromal Vascular Fraction in the Finger of Systemic Sclerosis Patients
NCT03060551 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
RENEW Scleroderma: A Peer-Mentored, Web Intervention for Resilience-based, Energy Management to Enhance Wellbeing and Fatigue
NCT04908943 ·Status: COMPLETED ·Phase: NA
-
Role of Eosinophil in Fibrogenesis of Systemic Sclerosis
NCT03816189 ·Status: COMPLETED
-
A Comparison Between Two Educational Methods in the Rehabilitation of the Microstomia in Systemic Sclerosis
NCT03766243 ·Status: COMPLETED ·Phase: NA